Post Reply
3381-3400 of 3892
Look like could test the support soon. Low volume always got sell down and slowly depreciate for this stock.
Need BB to take interest again.
Need BB to take interest again.
Back to fundamentals..
RS and most gloves companies will reverse trend due to elevated demands.
More profits will continue for a while until pandemiec is really over.
On the supply side, many of these companies have slow down expansion plan.
New entrants unlikely to do big to avoid more losses..
Anyway, just wait for next results announcement.. no hurry to sell when 10c dividend coming.
Dyodd is best.
Sometimes they buy up to cover shorts and then Q to sell same price for you to buy.
SYDNEY: Australia suffered its deadliest day of the pandemic on Tuesday (Jan 18) as a fast-moving Omicron outbreak continued to push up hospitalisation rates to record levels, even as daily infections eased slightly.
Australia is dealing with its worst COVID-19 outbreak, fuelled by the Omicron variant of the coronavirus that has put more people in hospitals and intensive care than at any time during the pandemic.
A total of 77 deaths was recorded, exceeding the previous national high of 57 last Thursday, official data showed.
Today, is a very difficult day for our state, New South Wales Premier Dominic Perrottet said during a media briefing as the state reported 36 deaths, a new pandemic high.
Only four of those who died in NSW had received their booster shot, prompting the state' s health officials to urge people to avoid delays and get their third dose soon. Thirty-three were double-dosed.
There needs to be a sense of urgency in embracing the booster doses, NSW Chief Health Officer Kerry Chant said. For Omicron, we know that the protection is lower and we need that next boosting to get that higher level of protection.
The surge in case numbers battered consumer confidence last week, an ANZ survey on Tuesday showed, triggering self-imposed lockdowns and stifling spending even as states looked to avoid lockdowns and keep businesses open...
The way they sell is very obvious.
The short sellers let you buy up then place a lower price for you to buy.
The buy Q are short sellers who once received a trade will cover short or place on sell Q.
End of day they might just dump what they collected from Buy Q to sell down.
The aim is always to sell down and Q just above for buyers to buy
ksangks ( Date: 18-Jan-2022 15:55) Posted:
|
Dont sell , buy if have money . But how to know it is short selllers who are selling?
investor999 ( Date: 18-Jan-2022 15:53) Posted:
|
To all glove stock holders.
I am sure by now you would have noticed there is persistent short sellers.
Someone has been shorting and creating a downtrend.
Wavehunter bro says there will be a 10% correction.
Beware
Look like demand has increased but supplies have also increased more than demand .
RichardTeo ( Date: 18-Jan-2022 13:12) Posted:
|
Need big buyers like fund managers to buy , otherwise will always remain a retailer stock , up few cents , take profits and down and back to square one
Midtermer ( Date: 18-Jan-2022 07:47) Posted:
|
I think we are slowly shifting back to fundamentals once all the sentiments die down. The fy results will be critical and I am positive RS will do well compared to its peers. UG may surprise as well as its focus is in Europe. Dyodd.
ksangks ( Date: 18-Jan-2022 07:36) Posted:
|
But not helping glove stocks like last year.
RichardTeo ( Date: 18-Jan-2022 06:52) Posted:
|
Exactly but why only retail investors attracted to this ?
RichardTeo ( Date: 17-Jan-2022 16:47) Posted:
|
They will continue to cash up as they will generate more profits every qtr..
RM1.8b in cash or equiva..
RichardTeo ( Date: 17-Jan-2022 16:30) Posted:
|
Greed and fear always stoke retailers.
If in doubt, see what the CEO and his SSH do..
Buy or sell , they know best.
PE ratio cannot stay at current 3 times when the profitable company has 1.8b in cash and their dividend declared about 50%.
Results out next month and believe price should not stay low for long imho.
If in doubt, see what the CEO and his SSH do..
Buy or sell , they know best.
PE ratio cannot stay at current 3 times when the profitable company has 1.8b in cash and their dividend declared about 50%.
Results out next month and believe price should not stay low for long imho.
Wiil not add but will not sell also.
Sometimes we really doubt we see values but why BBs don' t see the values we saw ? Retail investors better foresight than the BBs ?
If really so good and real , why market not reacting to it's fundamentals ?
RS Q3 UPDATE:
Operational Review
Demand for the Group&rsquo s healthcare examination gloves has continued to grow despite the pandemic moving into the endemic phase in many parts of the world. Market prices however have begun to normalise progressively in 3Q2021 as major distributors have taken a wait-and-see approach for glove prices to stabilise.
On the other hand, demand for the Group&rsquo s high-tech cleanroom gloves remains robust, driven by a sustained growth in orders from the Group&rsquo s long-term customers within the electronics, semiconductors, batteries, sensors and lenses manufacturers. As a result of the above, the Group recorded a 35.3% year-on-year (yoy) increase in revenue to RM652.8 million for 3Q2021.
Similarly, gross profit rose 42.0% yoy to RM357.2 million for 3Q2021, as average selling prices remain comparatively higher than pre-pandemic levels. Collectively, the Group recorded a blended gross profit margin of 54.7% for 3Q2021.
Overall, this led the Group to post a 49.2% yoy increase in net profit attributable to shareholders to RM266.4 million for 3Q2021.
The Group continues to generate strong operating cash flows of RM449.0 million for 3Q2021 which has contributed to the resiliency of its balance sheet. Supported by cash and cash equivalents of RM1.8 billion as at 30 September 2021, the Group remains in a strong position to further its capacity expansion plans and navigate the prevailing industry headwinds.
Outlook
For Phase 7 of the Group&rsquo s capacity expansion plans, the Group faced temporary delays as a result of the disruption to construction and other related works caused by the Movement Control Order (MCO) in Malaysia. Accordingly, the additional 1.5 billion pieces of new production capacity for Phase 7 will come online by 1Q2022.
Beyond Phase 7, preparations for the Group&rsquo s latest production facility for Phase 8 is currently underway. Subject to prevailing market conditions, Phase 8 is slated to add up to 1.5 billion pieces of gloves to bring the total annual production capacity of the Group by up to 13.5 billion by FY2022/23.
Executive Chairman and CEO, Mr. Wong Teek Son (黄 德 顺 ) remarked, While we remain cognisant of the current industry situation, we continue to set our sights on longer-term prospects to achieve sustainable growth.
For one, our differentiated business model driven by our industry leading cleanroom glove business will provide the necessary support as we navigate the evolving healthcare glove market.
We will also continue our focus on developing new and innovating products to diversify our income streams by capturing new market segments, namely in food processing, pharmaceutical as well as surgical glove segments to fuel growth.
Backed by our robust financial position and the continued support of our long-term customers, we are confident of navigating the near-term headwinds and remain positive of our future prospects.
Operational Review
Demand for the Group&rsquo s healthcare examination gloves has continued to grow despite the pandemic moving into the endemic phase in many parts of the world. Market prices however have begun to normalise progressively in 3Q2021 as major distributors have taken a wait-and-see approach for glove prices to stabilise.
On the other hand, demand for the Group&rsquo s high-tech cleanroom gloves remains robust, driven by a sustained growth in orders from the Group&rsquo s long-term customers within the electronics, semiconductors, batteries, sensors and lenses manufacturers. As a result of the above, the Group recorded a 35.3% year-on-year (yoy) increase in revenue to RM652.8 million for 3Q2021.
Similarly, gross profit rose 42.0% yoy to RM357.2 million for 3Q2021, as average selling prices remain comparatively higher than pre-pandemic levels. Collectively, the Group recorded a blended gross profit margin of 54.7% for 3Q2021.
Overall, this led the Group to post a 49.2% yoy increase in net profit attributable to shareholders to RM266.4 million for 3Q2021.
The Group continues to generate strong operating cash flows of RM449.0 million for 3Q2021 which has contributed to the resiliency of its balance sheet. Supported by cash and cash equivalents of RM1.8 billion as at 30 September 2021, the Group remains in a strong position to further its capacity expansion plans and navigate the prevailing industry headwinds.
Outlook
For Phase 7 of the Group&rsquo s capacity expansion plans, the Group faced temporary delays as a result of the disruption to construction and other related works caused by the Movement Control Order (MCO) in Malaysia. Accordingly, the additional 1.5 billion pieces of new production capacity for Phase 7 will come online by 1Q2022.
Beyond Phase 7, preparations for the Group&rsquo s latest production facility for Phase 8 is currently underway. Subject to prevailing market conditions, Phase 8 is slated to add up to 1.5 billion pieces of gloves to bring the total annual production capacity of the Group by up to 13.5 billion by FY2022/23.
Executive Chairman and CEO, Mr. Wong Teek Son (黄 德 顺 ) remarked, While we remain cognisant of the current industry situation, we continue to set our sights on longer-term prospects to achieve sustainable growth.
For one, our differentiated business model driven by our industry leading cleanroom glove business will provide the necessary support as we navigate the evolving healthcare glove market.
We will also continue our focus on developing new and innovating products to diversify our income streams by capturing new market segments, namely in food processing, pharmaceutical as well as surgical glove segments to fuel growth.
Backed by our robust financial position and the continued support of our long-term customers, we are confident of navigating the near-term headwinds and remain positive of our future prospects.
If our brokers have a program to keep track of their own stocks of shares, any buying and selling will be amalgamated.
Some people might have sold earlier and they brokers have shares to sell.